Background: Current standard treatment, including non-anthracycline-based chemotherapy and optimal combining of radiotherapy, has dramatically improved outcomes of patients with extranodal natural killer/T-cell lymphoma (ENKTL) during the last decade. This study was conducted to investigate the clinical outcome of ENKTL patients with relapsed or progressive disease after initial current standard therapy.
Introduction
Extranodal natural killer/T-cell lymphoma (ENKTL) is a rare, aggressive subtype of non-Hodgkin lymphoma with a poor prognosis that is mainly observed in Asian and Latin American countries [1] . Because ENKTL is frequently resistant to the conventional anthracycline-based chemotherapy used for other lymphomas [2, 3] , non-anthracycline-based chemotherapy regimens that incorporate L-asparaginase (L-Asp) have been used since the late 2000s and have improved survival outcome in patients with advanced-stage, relapsed, or refractory ENKTL [4] [5] [6] . In addition, for localized disease, optimal combination of radiotherapy with non-anthracycline-based chemotherapy, either concurrent or sequential, is reportedly better than anthracycline-based chemotherapy such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens [7, 8] .
The overall prognosis of ENKTL has certainly improved in the era of non-anthracycline-based chemotherapy regimens. However, a substantial number of patients, especially those with advanced disease, still experience progression or relapse after initial treatment [9] . Previously, Mak et al. reported short survival outcomes in 153 patients with relapsed or refractory peripheral T-cell lymphoma subtypes [10] . Median overall survival (OS) and median progression-free survival (PFS) after relapse or progression were 5.5 and 3.1 months, respectively. From these findings, we can assume that the survival of patients with ENKTL after relapse or progression is poor; however, data regarding clinical outcomes in relapsed and refractory ENKTL in the era of non-anthracycline-based regimens are scarce. In the absence of information on the efficacy of novel drugs or standard therapies for relapsed or refractory ENKTL, it remains challenging to explore the efficacy of salvage chemotherapy regimens as bridges to stem-cell transplantation (SCT) or palliative therapy.
In this study, we investigated the spectrum of survival in a relatively large cohort of patients with ENKTL after relapse or progression beyond non-anthracycline-based chemotherapy, explored factors influencing survival, and compared the efficacy and clinical outcomes of different salvage chemotherapy regimens.
Methods

Study design and participants
We carried out a multi-center retrospective study of patients diagnosed with ENKTL in six hospitals in four countries (China, France, Singapore, and South Korea). Patients who met the following criteria were eligible for enrollment: (i) pathologically confirmed ENKTL according to the World Health Organization (WHO) classification; (ii) relapsed or progressive disease (PD) after initial current standard treatment. In this study, we defined the current standard treatment as non-anthracyclinebased combination chemotherapy for advanced stage disease and optimal combining of radiotherapy for localized disease. Response to primary therapy and clinical and laboratory parameters at the time of relapse were manually recorded, including age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, Ann Arbor stage, number of extranodal involvement sites, serum lactate dehydrogenase (LDH) level, International Prognostic Index (IPI) and Korean Prognostic Index (KPI). In addition, our new clinical-pathological prognostic indices, the prognostic index of natural killer lymphoma (PINK) [9] and PINK-E (Epstein-Barr virus), were included for eligible patients.
Treatment
Current standard treatment of patients with early-stage ENKTL incorporates radiotherapy in the form of concurrent chemoradiation therapy (CCRT), sequential chemoradiation, or sandwich chemoradiation. At initial presentation with advanced stage disease, patients were treated with non-anthracycline-based chemotherapy. Various combination chemotherapy regimens were used, with SMILE (dexamethasone, methotrexate, ifosfamide, L-Asp, and etoposide) as the most commonly used regimen, followed by gemcitabine-containing regimens such as GEMOX (gemcitabine, oxaliplatin) or GIFOX (gemcitabine, ifosfamice, and oxaliplatin). Some patients underwent upfront autologous SCT after SMILE chemotherapy. At the time of progression or relapse, patients were treated with salvage chemotherapy according to the treating physician's discretion.
Statistical analysis
OS was calculated from date of relapse or progression to date of last follow-up or death from any cause. Second PFS was calculated from date of first relapse or progression to date of second progression or relapse, death resulting from any cause, or last follow-up. Survival analysis was carried out using the Kaplan-Meier method, and survival comparisons were made using the log-rank test. We carried out Cox regression analyses to assess the association between baseline patient characteristics at relapse and both PFS and OS, which are reported as hazard ratio (HR) with 95% confidence intervals (CI). All statistical analyses were carried out using SPSS software (version 21; SPSS Inc., Chicago, IL), and a P value (two-tailed) <0.05 was considered statistically significant.
Results
Patients
Between 1997 and 2015, a total of 179 patients [South Korea (n ¼ 108), France (n ¼ 17), China (n ¼ 31), and Singapore (n ¼ 23)] met inclusion criteria and were analyzed, including 112 males (63%) and 67 females (37%) with a median age of 50 years (range 17-80) ( Table 1 ). Median time from initial ENKTL diagnosis to relapse or progression was 6.5 months (range 0.2-64.2). Baseline patient characteristics at the time of relapse or progression are listed in Table 1 . At relapse B symptom and elevated LDH levels were observed in 43% and 62% of the patients, respectively. About two-thirds of patients at relapse or progression presented with advanced disease (63%). As a first-line treatment, $35% of patients received concurrent or sequential CRT, whereas 65% (117 patients) received chemotherapy alone. Fewer than half experienced PD after initial therapy (41%), and relapse occurred in 68 patients (39%) after complete response (CR) and in 36 patients (20%) after partial response (PR). Upfront autologous SCT was carried out in nine patients.
Outcomes and prognostic factors
After a median follow-up of 58.6 months (range 27.9-89.2), the median OS was 6.4 months (95% CI 4.36-8.51) and median PFS after relapse (i.e. second PFS) of all patients was 4.1 months (95% CI 3.04-5.16) (Figure 1 ). Multivariate analysis showed that elevated LDH levels, multiple extranodal sites (!2), and presence of B symptoms at the time of relapse/progression were significantly associated with inferior OS ( Table 2) .
The median OS was 9.0 months for the L/LI IPI group, and 3.5 months for the HI/H IPI group (P < 0.001). Patients with NKPI III/IV at relapse showed significantly shorter OS than those with NKPI I/II (median OS, 4.3 versus 26.5 months; P < 0.001) and there were also significant differences in second PFS among IPI and NKPI risk groups (supplementary Figure S1 , available at Annals of Oncology online). OS and PFS were also significantly better for patients in the low-risk group according to PINK or PINK-E than those in the intermediate or high-risk group (median OS by PINK: Low 26.5 versus Intermediate 7.9 versus High 4.3 months, P < 0.001; median OS by PINK-E: Low 9.0 versus Intermediate 4.6 versus High 4.3 months, P < 0.001) (Figure 1 ).
Salvage treatment
In total, 135 patients (75.4%) received salvage therapy after relapse, including RT, CCRT, chemotherapy, and chemotherapy followed by SCT. The remainder (24.6%) received supportive care only and/or corticosteroids mainly due to older age and poor performance. Five patients who relapsed with localized disease received RT or CCRT alone and 28 underwent SCT (25 autologous SCT and 3 allogeneic SCT) after salvage chemotherapy. As expected, patients who received SCT showed significantly longer OS compared with those without SCT (median OS: 20.6 versus 6.0 months, P ¼ 0.010). The median OS and second PFS were significantly higher in patients receiving salvage chemotherapy than in those receiving supportive care only (supplementary Figure S2 , available at Annals of Oncology online). Thirty-six patients who achieved CR to salvage chemotherapy showed markedly better survival compared with those with PR (median OS: 125.9 versus 8.9 months). Among salvage chemotherapy regimens, the most commonly used were L-Asp-containing regimens (n ¼ 63, 48.5%) such as SMILE, VIDL, and AspaMetDex and gemcitabine-containing regimens (n¼29, 22.3%) such as GDP, GIFOX, and GEMOX (n ¼ 29, 22.3%) (supplementary Table S1 , available at Annals of Oncology online). Overall response rate (ORR) to salvage therapy was 44.8% (13/29) in the gemcitabine-based chemotherapy group and 58.7% (37/63) in the L-Asp-based chemotherapy group (supplementary Table S2 , available at Annals of Oncology online). Among 130 patients treated with salvage chemotherapy, the median second PFS was significantly better in the L-Asp-based chemotherapy group compared with those who received gemcitabine-containing regimens or other chemotherapeutic agents (P ¼ 0.034) (supplementary Figure S2 , available at Annals of Oncology online). In all 63 patients treated with salvage chemotherapy with an L-Asp-based regimen, we compared the efficacy of L-Asp-containing chemotherapy between patients re-treated with L-Asp and those who received L-Asp for the first time as salvage therapy. Patient characteristics with regard to IPI, NKPI, PINK/PINK-E were comparable between the two groups, except for the time of relapse (<6 versus !6 months) (supplementary Table S3 , available at Annals of Oncology online). ORR was much better in patients with first use of L-Asp in comparison with those with rechallenge of the drug (74.2% versus 43.7%). Of note, ORR to rechallenge L-Asp-containing therapy according to the time of relapse (!6 months) was relatively high at 50% (14/28), whereas none of the four patients re-treated with L-Asp within 6 months showed a response. Median OS and PFS were significantly improved in the first use of L-Asp group compared with the rechallenge group (OS: 27.1 versus 7.0 months, P ¼ 0.012; PFS: 15.7 versus 4.0 months, P ¼ 0.025) (Figure 2 ).
Discussion
It has been established that outcome for patients with ENKTL improves after application of non-anthracycline-based chemotherapy and optimal combining of radiotherapy such as CCRT, sequential CRT, or sandwich CRT. For early-stage disease, especially the nasal type, systemic chemotherapy combined with involved-field radiotherapy has substantially improved long-term survival beyond 60%-70% [11] . Even in patients with advanced disease, L-Asp-based chemotherapy such as the SMILE regimen has promising efficacy [4, 6, 12] compared with conventional anthracycline-containing chemotherapy [13] . However, relapse or progression continues to occur, and treatment of ENKTL that relapses or is refractory to first-line treatment represents an unmet medical need.
Overall prognosis for these patients was poor. The median OS was only 6.4 months and second PFS after relapse or progression was 4.1 months. ENKTL patients in this multicenter cohort who were either refractory to primary therapy or relapsed represented a poor-risk population. In addition, we confirmed that elevated LDH level and presence of B symptoms were also critical prognostic factors associated with inferior survival.
Both IPI and NKPI score obtained at time of relapse/progression were strongly able to discriminate patients into two groups (L/LI versus HI/H and I/II versus III/IV, respectively) with different survival outcomes. Because those prognostic systems were established based on anthracycline-based chemotherapy, we attempted to apply the new prognostic models of PINK/PINK-E in the current study [9] . The PINK and PINK-E models also explicitly separated the survival curves into three category risk groups (low-, intermediate-, and high-risk).
At present, no standard treatment is available for patients with refractory or relapsed ENKTL and the optimal treatment strategy remains largely unknown, especially for those previously treated with non-anthracycline-based chemotherapy with or without RT. In the present study, among 130 patients who received salvage chemotherapy, about half (48%) were treated with an L-Asp-based combination chemotherapy regimen, and the second most commonly used regimen was gemcitabine-based chemotherapy (22%). Previously, gemcitabine-containing chemotherapy showed relatively good results in terms of ORR in pretreated ENKTL patients [14] . In this study, among 29 patients treated with gemcitabine-based chemotherapy regimen as salvage therapy, an ORR of $45% was achieved. Given the high expression of multidrug-resistant P-glycoprotein in NK cells, L-Asp is well known for its unique antitumor activity. A previous phase II trial proved the efficacy of AspaMetDex (L-Asp, methotrexate, and dexamethasone) in 19 patients with relapsed/refractory ENKTL with an ORR of 78% [5] . In contrast, a recent study showed that L-Asp-containing salvage chemotherapy failed to confer a survival advantage over chemotherapy lacking L-Asp in relapsed ENKTL (5-year OS: 44.2% versus 39.3%, P ¼ 0.369) [15] . Our study confirmed that an L-Asp-containing regimen had a modest effect (ORR 58.7%, CR 38.1%) in patients previously treated with non-anthracycline-based chemotherapy. There was a significant difference in terms of PFS between L-Asp-based chemotherapy, gemcitabine-based chemotherapy, and other regimens (P ¼ 0.025). A survival gain was probably not observed due to the relatively short duration of response. Thirty-two out of 63 patients received demonstrated efficacy in patients with relapsed or refractory ENKTL [17, 18] . Regarding novel therapeutic agents in ENKTL, our pilot study suggested that the histone deacetylase (HDAC) inhibitor romidepsin might cause fatal EBV reactivation in patients with ENKTL [19] . HDAC inhibitors safety issues in ENKTL require further research. Given that CD30 expression was noted in a relatively high percentage of ENKTL [20] , brentuximab vedotin (BV) could be considered a therapeutic option as either single or combination therapy. We reported a case of a heavily treated ENKTL patient with a tumor that expressed CD30 who achieved CR after treatment with single-agent BV [21] and Kwong et al. recently reported that refractory ENKTL with CD30 expression was completely resolved after treatment with combined BV and bendamustine [22] . JAK/STAT signaling pathways are suggested to be crucial in the lymphomagenesis of ENKTL [23] and recent next-generation sequencing study showed that JAK/STAT pathway-related genes were associated with ENKTL pathogenesis [24, 25] . In addition, anti-programmed death 1 antibodies such as nivolumab and pembrolizumab recently showed encouraging response rates in malignant lymphoma [26] . Although these findings need to be validated in further studies they may lead to personalized treatment of ENKTL.
In conclusion, we confirmed poor outcome in patients with relapsed and refractory ENKTL who were initially treated with current standard non-anthracycline-based therapy, as well as the need to develop more efficient chemotherapy or novel agents that are specifically active in ENKTL.
